- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | RADIOPHARM THERANOSTICS LIMITED: Half Year Report and Appendix 4D 31 December 2025 | 2 | ASX | ||
| 24.02. | AtomVie Global Radiopharma Inc.: AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01) | 322 | PR Newswire | HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first... ► Artikel lesen | |
| 24.02. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.02. | Radiopharm doses first patient in phase 1/2a cancer trial | 1 | Investing.com | ||
| 24.02. | Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) | 214 | GlobeNewswire (Europe) | First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center Preclinical animal studies of BetaBart (RV-01) have... ► Artikel lesen | |
| 24.02. | Radiopharm Theranostics Doses First Patient in RV-01 Phase 1/2a Trial for Aggressive Cancers | 2 | smallcaps.com.au | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 23.02. | RADIOPHARM THERANOSTICS LIMITED: RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study | - | ASX | ||
| 28.01. | Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates | 291 | GlobeNewswire (Europe) | Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim... ► Artikel lesen | |
| 28.01. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.01. | RADIOPHARM THERANOSTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 12.01. | Radiopharm Theranostics: RAD Increases Ownership in Radiopharm Ventures to 87.5% | 225 | GlobeNewswire (Europe) | Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received... ► Artikel lesen | |
| 12.01. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.01. | RADIOPHARM THERANOSTICS LIMITED: RAD Increases Ownership in Radiopharm Ventures to 87.5% | - | ASX | ||
| 07.01. | RADIOPHARM THERANOSTICS LIMITED: Change in substantial holding | 1 | ASX | ||
| 23.12.25 | RADIOPHARM THERANOSTICS LIMITED: Notification of cessation of securities - RAD | 1 | ASX | ||
| 19.12.25 | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (RC) | - | ASX | ||
| 19.12.25 | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (PH) | - | ASX | ||
| 19.12.25 | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (IT) | - | ASX | ||
| 19.12.25 | RADIOPHARM THERANOSTICS LIMITED: Notification regarding unquoted securities - RAD | - | ASX | ||
| 18.12.25 | RADIOPHARM THERANOSTICS LIMITED: Proposed issue of securities - RAD | 1 | ASX |
1 2 3 4 5 Weiter >>
100 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 90,10 | 0,00 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| VERA THERAPEUTICS | 40,420 | 0,00 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ADMA BIOLOGICS | 16,580 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| QIAGEN | 41,385 | +0,22 % | Shortseller-Positionen aktuell: freenet, GFT, HelloFresh, Hypoport, Puma, Qiagen, Redcare Pharmacy | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| TREVI THERAPEUTICS | 12,570 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| EVOTEC | 5,358 | -5,77 % | Evotec: Das Biotech-Drama geht in die nächste Runde | Die Aktie des Hamburger Wirkstoffforschers Evotec versucht erneut den Befreiungsschlag, doch das Misstrauen am Markt ist greifbar. Nach einer beispiellosen Serie von Rückschlägen - von Management-Skandalen... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,92 | 0,00 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| BIONTECH | 90,10 | -2,12 % | BioNTech SE: BioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 24. Februar 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 10. März 2026, die Ergebnisse für das vierte Quartal und... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 330,19 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 32,520 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 17,680 | 0,00 % | Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential | ||
| KINIKSA PHARMACEUTICALS | 46,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,890 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,145 | +3,36 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,190 | 0,00 % | H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty |
Das Unternehmen RADIOPHARM THERANOSTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,00 % bei einem Aktienkurs von 4,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.